Ultragenyx Pharmaceutical Inc.

Healthcare · Biotechnology · United States

Last price 16.78 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.65B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment...